Abstract 1641P
Background
Gemcitabine (Gem) and nab-paclitaxel (Nab) is a standard treatment for pts with inoperable pancreatic cancer (iPC), but a high frequency of chemoresistance is observed clinically. SCO-101 is a compound for oral use that was shown to revert drug resistance in preclinical studies: In taxane-resistant cancer cells SCO-101 resensitized tumor cells to taxane and reduced the active efflux of ATP Binding Cassette G2 substrate molecules from irinotecan resistant colon cancer cells. Moreover, SCO-101 inhibits Serinine-Arginine Protein Kinase 1, which may increase sensitivity of tumor cells to Gem. In clinical phase I studies, SCO-101 was well tolerated after single (up to 200 mg) and multiple (up to 150 mg daily for 14 days) doses.
Methods
This open-label, phase Ib study was conducted at four centers in Denmark and Germany as a standard 3+3 dose escalation study with increasing doses of SCO-101 and 80% dose of Gem-Nab in pts with iPC. Here we report on the primary objective to determine safety and Maximum Tolerated Dose (MTD) by evaluation of Dose-Limiting Toxicities (DLTs) related to SCO-101 during the first treatment cycle.
Results
22 pts were included. Median age was 65 years (range 51-77) and 16 had ECOG PS=0. 11 pts had prior PC-related surgery and 19 had previously received chemotherapy. SCO-101 was dosed once daily for 6 days on days 1-6 and 15-20 on a bi-weekly schedule and chemotherapy given on day 6, 13 and 20. MTD was determined to be 200mg (Table). DLTs included increased conjugated bilirubin and decreased platelet count.
Table: 1641P
Results of dose escalation
Cohort | No of pts | No of DLTs | Type and grade of DLT (Graded according to CTC ver. 5.0) |
50 mg of SCO-101 | 3 | 0 | |
100 mg SCO-101 | 3 | 0 | |
150 mg SCO-101 | 6 | 1 | Conjugated bilirubin gr. 3 |
200 mg SCO-101 | 6 | 0 | |
250 mg SCO-101 | 4 | 2 | Decreased platelet count gr. 4 |
Total | 22 | 3 |
Conclusions
The combination of SCO-101 and Gem-Nab was generally well tolerated. DLTs were observed in 2 pts in the cohort treated with 250mg of SCO-101, hence MTD for SCO-101 concurrent with Gem-Nab was determined to be 200mg once daily for 6 days on a bi-weekly schedule. A full description of toxicities is pending.
Clinical trial identification
NCT04652206.
Editorial acknowledgement
The authors M.L and S.S contributed equally.
Legal entity responsible for the study
Region Nordjylland.
Funding
Scandion Oncology A/S.
Disclosure
M. Ladekarl: Financial Interests, Institutional, Research Grant: Scandion Oncology A/A. A. Reinacher-Schick: Financial Interests, Personal, Invited Speaker: Amgen, Roche, Merck, Bristol Myers Squibb, MSD, MCI Group, AstraZeneca; Financial Interests, Personal, Advisory Board: Amgen, Roche, Merck, Bristol Myers Squibb, AstraZeneca, Pierre Fabre; Financial Interests, Personal, Other, Travel support: Roche, Amgen, Pierre Fabre; Financial Interests, Institutional, Research Funding: Roche, Ipsen, Roche, Celgene, Ipsen, Amgen, Alexion Pharmaceuticals, AstraZeneca, Lilly, Servier, AIO Studien GmbH, Rafael Pharmaceutics, Erytech Pharma, BioNTech. J. Stenvang: Financial Interests, Personal, Stocks/Shares: Scandion Oncology A/S; Financial Interests, Personal, Full or part-time Employment: Scandion Oncology A/S; Financial Interests, Personal, Other, Co-founder: Scandion Oncology A/S. A. Zurlo: Financial Interests, Personal, Full or part-time Employment: Scandion Oncology A/S. N. Lindland Roest: Financial Interests, Personal, Full or part-time Employment: Scandion Oncology A/S. All other authors have declared no conflicts of interest.
Resources from the same session
1677P - Pancreatic enzyme replacement therapy improves survival in patients receiving nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma
Presenter: Daniele Lavacchi
Session: Poster session 22
1678P - A retrospective real-world study of nimotuzumab combined with chemotherapy for first-line treatment of advanced pancreatic cancer: A single center propensity score matched analysis
Presenter: Yinying Wu
Session: Poster session 22
1679P - Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: A systematic review and network meta-analysis
Presenter: Luca Mastrantoni
Session: Poster session 22
1680P - Meta-analysis of real-world survival outcomes of liposomal irinotecan in advanced pancreatic cancer patients with prior irinotecan exposure
Presenter: Amol Gupta
Session: Poster session 22
1681P - A retrospective real-world study for nimotuzumab plus postoperative adjuvant chemotherapy for resectable pancreatic cancer
Presenter: Siyi Zou
Session: Poster session 22
1682P - Impact of metastatic site on survival in patients with synchronous metastatic pancreatic adenocarcinoma (PDAC): A national prospective BACAP study
Presenter: Emily Alouani
Session: Poster session 22
1683TiP - Trial in progress: NEO-adjuvant chemo-IMmunotherapy in PAnCreaTic cancer-NEO-IMPACT
Presenter: Sarah Maloney
Session: Poster session 22
1684TiP - PARPiPANC: A multicentric, single arm, phase II assessing niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer
Presenter: Philippe Cassier
Session: Poster session 22
1685TiP - Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): A multicenter randomized controlled trial
Presenter: Jacob van Dam
Session: Poster session 22
1686TiP - Olaparib and durvalumab (MEDI4736) phase II study in patients with metastatic pancreatic cancer and DNA damage repair genes alterations
Presenter: Teresa Macarulla
Session: Poster session 22